Regenxbio Inc., of Rockville, Md., said it inked an exclusive global license agreement with Biogen Inc., of Cambridge, Mass., to develop gene therapy candidates based on its recombinant adeno-associated virus (AAV) gene therapy platform, dubbed NAV, to treat two rare genetic vision disorders.